First it was MDV-3100, then it morphed into Enzalutamide only to finally emerge as "Xtandi" What ? Who ? Where is Xtandi coming from, it sounds like a second hand mobile phone but I guess the marketing guys at Medivation know what they are doing. The FDA approval of Xtandi for prostate cancer patients that have received docetaxel chemotherapy launches Xtandi as a rival to Zytiga so it will be interesting to see how they compete head to head in the post chemotherapy setting. Xtandi Vs Zytiga game on !
No comments:
Post a Comment